These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Models of Prognostication in Chronic Myelomonocytic Leukemia. Onida F Curr Hematol Malig Rep; 2017 Dec; 12(6):513-521. PubMed ID: 29064026 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Onida F; Kantarjian HM; Smith TL; Ball G; Keating MJ; Estey EH; Glassman AB; Albitar M; Kwari MI; Beran M Blood; 2002 Feb; 99(3):840-9. PubMed ID: 11806985 [TBL] [Abstract][Full Text] [Related]
15. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China. Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982 [TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease? Voglová J; Chrobák L; Neuwirtová R; Malasková V; Straka L Leuk Res; 2001 Jun; 25(6):493-9. PubMed ID: 11337023 [TBL] [Abstract][Full Text] [Related]
17. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070 [TBL] [Abstract][Full Text] [Related]
18. Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia. Lackner D; Geissler K Wien Med Wochenschr; 2023 Feb; 173(1-2):27-33. PubMed ID: 36414855 [TBL] [Abstract][Full Text] [Related]
19. Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes. Harrington AM; Schelling LA; Ordobazari A; Olteanu H; Hosking PR; Kroft SH Am J Clin Pathol; 2016 Aug; 146(2):170-81. PubMed ID: 27413139 [TBL] [Abstract][Full Text] [Related]
20. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]